Unique Factors Impact Outcome in AYA Patients with Cancer
Characteristics of cancer in adolescents and young adults are defined and suggestions provided to improve survival
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1551 results
Exploratory Analysis of FIRE-3 According CRC Consensus Molecular Subgroups
Molecular classification provides deeper insights into biology of colorectal cancer, but at present time with no impact on clinical decision-making
Adding Isatuximab to Pomalidomide and Low-Dose Dexamethasone Improves PFS in Relapsed and Refractory Multiple Myeloma
Important advance in the management of patients who represent an otherwise unmet medical need
FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma
Evidence for efficacy is based on the results from BGB-3111-206 and BGB-3111-AU-003 studies
EMA Recommends Extension of Indications for Trastuzumab Emtansine
New indication concerns adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease
Secondary Surgical Cytoreduction Followed by Chemotherapy vs Chemotherapy in Recurrent Ovarian Cancer
The results of the GOG-0213 study
Clinical Benefit of Pembrolizumab in Previously Treated Advanced MSI-H/dMMR Non-colorectal Cancers
The results of KEYNOTE-158 study
Divergent HLA Allele Linked to Immunotherapy Efficacy
Researchers uncover how immune checkpoint inhibitor response relies on the evolved efficiency of HLA-mediated immunity
FDA Approves Luspatercept-aamt for Anaemia in Patients with Beta Thalassemia
Evidence for efficacy is based on the results from the BELIEVE trial
Cancer-Related Cognitive Impairment in Cancer Survivors
Detection and management strategies
Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung Cancer
The results of the AcSé phase II study
Efficacy and Biomarker Analysis of Neoadjuvant Immune Checkpoint Blockade in Urothelial Cancer
Findings from the ABACUS trial